Skip to main content
Premium Trial:

Request an Annual Quote

NCI/Celera Deal Gives Researchers Power to Choose, but Wellcome Trust Stands by its Ban


Last week’s decision by the National Cancer Institute to permit individual principal investigators to purchase access to Celera’s database was hailed by Celera and NCI alike as a conciliatory conclusion to the often ugly rivalry between the company and the publicly funded Human Genome Project.

“In some ways, it’s a validation of the American way, which is to start competition,” said Stephen O’Brien, chief of the NCI’s laboratory of genomic diversity.

An apt point, considering that the NIH’s European counterpart, the Wellcome Trust, is sticking by its official policy that forbids researchers to spend Wellcome Trust funds on Celera’s data. A spokeswoman from the Wellcome Trust, which drafted a prepared policy statement on the issue upon publication of the human genome sequence papers in February, told BioInform that the Trust has no plans to change its policy in light of the NCI decision.

The Wellcome Trust has been a vocal opponent of paying Celera for information freely available through resources it has funded. It recently launched a large-scale advertising campaign to raise awareness of the free online data sources that it supports, and notes in its policy statement that “because the Trust has no evidence to suggest that the Celera database resources offer any significant scientific advantage over those currently available in the public domain, the Trust considers that the payment of subscription costs to access Celera database resources does not constitute a justifiable use of its funds.”

NIH takes a different view of the matter, however, and chose to address the sticky policy issue of whether it should spend public money on private data with a “free market” approach. “It’s up to the PIs whether they spend their budget on it or not,” said Craig Hyde, special assistant to the director for the NCI’s Center for Cancer Research. “The real pressure is on them — their budget is precious to them.”

Hyde noted that the memorandum of understanding signed by the NCI covers only intramural NCI grantees at the center’s Bethesda and Frederick, Md., campuses. Several other NIH agencies are currently in discussions with Celera to work out subscription agreements, he said.

In addition, the NIH would consider subscription offers from other companies, according to Michael Gottesman, NIH deputy director for intramural research.

Under the agreement, the first 45 principal investigators can purchase a one-year subscription for the Discovery System for $12,222. Prices drop to a minimum of $7,000 should 101 or more NCI investigators sign up. This rate covers the PI and three additional users. Up to 22 additional users in the person’s lab can get access for $500 each.

Hyde estimated that approximately 400 NCI researchers are eligible to subscribe.

— KH and BT

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.